- Gefitinib2010 | Central Library of Charles University
- Gefitinib +12010 | Faculty of Medicine in Pilsen
- Gefitinib2005 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Gefitinib drug profile2010 | Faculty of Medicine in Pilsen
- Urinary neopterin in patients treated with gefitinib2007 | Publication without faculty affiliation
- Gefitinib - experience on biological targeted therapy of non-small-cell-lung cancer2004 | Central Library of Charles University, Faculty of Medicine in Pilsen
- Gefitinib - experience on biological targeted therapy of non-small-cell-lung cancer2004 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- New drug profile - gefitinib (AstraZeneca)2005 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Results of clinical evaluation of gefitinib therapeutic activity and toxicity in early access programme of NSCLC treatment in Czech Republic2009 | Central Library of Charles University
- Results of clinical evaluation of gefitinib therapeutic activity and toxicity in early access programme of NSCLC treatment in Czech Republic2009 | Faculty of Medicine in Pilsen
- Gefitinib monotherapy in advanced non-small cell lung cancer harboring activating mutation of EGFR had significantly better treatment results comparing to standard chemotherapy - from clinical practice2010 | First Faculty of Medicine
- Results of clinical evaluation of gefitinib therapeutic activity and toxicity in early access programme of NSCLC treatment in Czech Republic2009 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- New drug profile - gefitinib (AstraZeneca)2005 | Faculty of Medicine in Pilsen
- Impact of EGFR and KRAS mutations on survival prognosis of NSCLC patients treated with tyrosine-kinase inhibitors: Comparison of gefitinib and erlotinib.2009 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Intestinal permeability, vitamin A absorption and serum alpha-tocopherol during therapy with gefitinib2010 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- LUX-LUNG 7 - new look at the first line treatment for patients with frequent EGFR mutations?2016 | Faculty of Medicine in Pilsen
- Follow-up of expensive pneumo-oncological treatment of advanced non-small cell lung cancer in the I. line of the TULUNG register in the Czech Republic2013 | Central Library of Charles University, Faculty of Medicine in Pilsen, First Faculty of Medicine
- The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib2011 | Third Faculty of Medicine
- Impact of EGFR and KRAS mutations on survival prognosis of NSCLC patients treated with tyrosine-kinase inhibitors: Comparison of gefitinib and erlotinib.2009 | Central Library of Charles University
- Impact of EGFR and KRAS mutations on survival prognosis of NSCLC patients treated with tyrosine-kinase inhibitors: Comparison of gefitinib and erlotinib.2009 | Faculty of Medicine in Pilsen
- Clinical registry TULUNG2012 | Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Five years lasting of biological targeted therapy in pulmonary adenocarcinoma patient2013 | Publication without faculty affiliation
- Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study2021 | Faculty of Medicine in Hradec Králové, Central Library of Charles University, Faculty of Medicine in Pilsen, First Faculty of Medicine
- Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study2008 | Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Intestinal permeability during gefitinib treatmentPublication without faculty affiliation
- Urinary neopterin in patients treated with gefitinib2007 | Faculty of Pharmacy in Hradec Králové, Central Library of Charles University
- Program časného přístupu - gefitinib: Tolerabilita léčbyPublication without faculty affiliation
- Molecular pathology of pulmonary carcinomas2014 | Third Faculty of Medicine
- Intestinal permeability, vitamin A absorption and serum alpha-tocopherol during therapy with gefitinib2010 | Central Library of Charles University